Dopamine receptor antagonism is associated not only with antipsychotic action, but also with the generation of extrapyramidal side-effects of antipsychotic medications. Positron emission tomography studies reveal that an approximate 60-70% blockade of the D2 receptors is required for typical antipsychotics to be efficacious, but a blockade of ≥ 75-80% results in acute extrapyramidal side-effects. The newer atypical antipsychotics have a lower propensity to produce extrapyramidal side-effects. A new class of antipsychotics with a novel pharmacological profile and improved tolerability have emerged, comprising the 'dopamine-serotonin system stabilizers' of which aripiprazole is the first agent. We present the case of a patient who developed parkinsonism during treatment with aripiprazole.
|Original language||English (US)|
|Number of pages||3|
|Journal||International Clinical Psychopharmacology|
|State||Published - Mar 2006|
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)